About the Authors

Kirill Litovkin

Contributed equally to this work with: Kirill Litovkin, Aleyde Van Eynde

Affiliation Laboratory of Biosignaling & Therapeutics, KU Leuven Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium

Aleyde Van Eynde

Contributed equally to this work with: Kirill Litovkin, Aleyde Van Eynde

Aleyde.VanEynde@med.kuleuven.be

Affiliation Laboratory of Biosignaling & Therapeutics, KU Leuven Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium

Steven Joniau

Affiliation Urology, University Hospitals Leuven & KU Leuven Department of Development and Regeneration, University of Leuven, Leuven, Belgium

Evelyne Lerut

Affiliation Pathology, University Hospitals Leuven & KU Leuven Department of Imaging and Pathology, University of Leuven, Leuven, Belgium

Annouschka Laenen

Affiliation KU Leuven Biostatistics and Statistical Bioinformatics Centre, University of Leuven, Leuven, Belgium

Thomas Gevaert

Affiliation Urology, University Hospitals Leuven & KU Leuven Department of Development and Regeneration, University of Leuven, Leuven, Belgium

Olivier Gevaert

Affiliations Stanford Center for Cancer Systems Biology, Stanford University School of Medicine, Stanford, California, United States of America, Laboratory of Cancer Data Fusion, KU Leuven Department of Oncology, University of Leuven, Leuven, Belgium

Martin Spahn

Affiliations Department of Urology, University Hospital Bern, Inselspital, Bern, Switzerland, Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany

Burkhard Kneitz

Affiliation Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany

Pierre Gramme

Affiliation DNAlytics SA, Chemin du Cyclotron 6, 1348 Louvain-la-Neuve, Belgium

Thibault Helleputte

Affiliation DNAlytics SA, Chemin du Cyclotron 6, 1348 Louvain-la-Neuve, Belgium

Sofie Isebaert

Affiliation Radiation Oncology, University Hospitals Leuven & KU Leuven Department of Oncology, University of Leuven, Leuven, Belgium

Karin Haustermans

Affiliation Radiation Oncology, University Hospitals Leuven & KU Leuven Department of Oncology, University of Leuven, Leuven, Belgium

Mathieu Bollen

Affiliation Laboratory of Biosignaling & Therapeutics, KU Leuven Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium

Competing Interests

A GB patent, entitled 'Marker gene based prognosis of prostate cancer', was filed in UK with priority date of January 27, 2014 (GB1401371.8), and with AVE, KL and MB as inventors. TH is the CEO and Pierre Gramme the principal analyst of DNAlytics, SA (Chemin du Cyclotron 6, 1348 Louvain-la-Neuve, Belgium). This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: AVE KL SJ MB. Performed the experiments: KL. Analyzed the data: KL AVE SJ AL TG OG PG TH MB. Contributed reagents/materials/analysis tools: EL MS BK SI. Wrote the paper: AVE KL SJ KH MB. Pathological analysis: EL.